Cargando…
A meta-analysis of cisplatin-based concurrent chemoradiotherapy with or without cetuximab for locoregionally advanced nasopharyngeal carcinoma
BACKGROUND: It is unclear whether cetuximab (CTX) plus cisplatin-based concurrent chemoradiotherapy (CCRT) delivers equivalent or improved results over standard CCRT in locoregionally advanced nasopharyngeal carcinoma (NPC). METHODS: The strategy involved searching the PubMed, Embase, Cochrane Libra...
Autores principales: | Wang, Bi-Cheng, Shi, Liang-Liang, Fu, Chen, Zhou, Hong-Xia, Zhang, Zhan-Jie, Ding, Qian, Peng, Gang |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer Health
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6824634/ https://www.ncbi.nlm.nih.gov/pubmed/31626102 http://dx.doi.org/10.1097/MD.0000000000017486 |
Ejemplares similares
-
Durable response of tislelizumab plus cisplatin, nab-paclitaxel followed by concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma: A case report
por: Tang, Haifeng, et al.
Publicado: (2023) -
Cetuximab concurrent with IMRT versus cisplatin concurrent with IMRT in locally advanced nasopharyngeal carcinoma: A retrospective matched case–control study
por: Wu, Xin, et al.
Publicado: (2016) -
The efficacy and toxicity of induction chemotherapy plus concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma: A meta-analysis of randomized controlled trials
por: Wang, Peirong, et al.
Publicado: (2020) -
Efficacy and toxicity of three concurrent chemoradiotherapy regimens in treating nasopharyngeal carcinoma: Comparison among cisplatin, nedaplatin, and lobaplatin
por: Liang, Xuexia, et al.
Publicado: (2022) -
Comparison of therapeutic efficacy and toxicity of docetaxel, cisplatin, and fluorouracil (TPF)-based induction chemotherapy plus concurrent chemoradiotherapy and chemoradiotherapy alone in locally advanced nasopharyngeal carcinoma
por: Chen, Ruijuan, et al.
Publicado: (2021)